Skip to main content

Table 1 Summary of the patient samples included in this study

From: Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer’s pathophysiology and susceptibility

 

Total

CTRLs

AD

Series

N

N

%F

%ε4+

Age

N

%F

%ε4+

Age

A) Mayo postmortem

365

173

35.3

26.0

71.7

192

51.6

63.0

73.5

B) All

10,842

6,175

54.4

23.4

77.6

4,667

61.1

62.3

76.6

Mayo Clinic

6,307

4,250

54.0

23.3

78.7

2,057

60.7

59.9

79.3

NCRAD

910

209

61.7

16.3

78.3

701

64.8

78.5

75.2

Norway

927

569

59.6

24.6

74.9

358

69.8

63.1

79.4

ARUK

2,698

1,147

51.6

24.2

74.7

1,551

58.0

58.0

73.0

  1. Demographic details are shown for (A) Samples taken from the cerebellum of autopsy-confirmed AD patients and controls and used for genotype versus mRNA analyses and (B) Samples from the Mayo Clinic, Indiana, Norway and Alzheimer’s Research UK (ARUK) Consortium case-control series used for the case-control association study. N; number of samples, %F; percent females, %ε4; percent APOE ε4 carriers, Age; years.